Skip to main content

Advertisement

Table 3 DMARD and glucocorticoid use by patient characteristics among MCBS respondents with rheumatoid arthritis between 2001 and 2006, weighted to the US Medicare population

From: Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey

  Total weighted number (in thousands) Any DMARD Non-biologic DMARD Biologic DMARD Oral Glucocorticoid Use
   N (%)*
Age, years      
   65 to 74 2,965 1,089 (37%) 1,021 (35%) 169 (6%) 1,010 (34%)
   75 to 84 1,338 328 (25%) 323 (24%) 31 (2%) 376 (28%)
   85+ 353 15 (4%) 15 (4%) 0 80 (23%)
Gender      
   Female 3,440 1,071 (31%) 1,014 (30%) 173 (5%) 1,104 (32%)
   Male 1,216 361 (30%) 346 (29%) 28 (2%) 361 (30%)
Race/ethnicity      
   Non-Hispanic, white 2,996 1,170 (33%) 1,145 (32%) 130 (4%) 1,186 (33%)
   Non-Hispanic, black 413 119 (25%) 111 (23%) 11 (2%) 141 (29%)
   Hispanic 364 90 (20%) 52 (12%) 60 (13%) 117 (26%)
   Non-Hispanic, other 133 52 (33%) 52 (33%) 0 22 (14%)
Income (US dollars)      
   >50,000 260 126 (49%) 126 (49%) 30 (12%) 98 (38%)
   >30,000 to 50.000 1,003 376 (38%) 353 (35%) 74 (7%) 353 (35%)
   >20,000 to 30,000 992 309 (31%) 278 (28%) 65 (7%) 373 (38%)
   >15,000 to 20,000 639 188 (30%) 175 (27%) 19 (3%) 175 (27%)
   ≤ 15,000 1,582 361 (23%) 358 (23%) 7 (0.5%) 392 (25%)
  1. Total number = 4,656,213. *Percentage of the row total. DMARD, disease modifying anti-rheumatic drug use; MCBS, Medicare Current Beneficiary Survey.